Tumores carcinoides bronquiales: Un estudio prospectivo

Pareja, Eugenia; Arnau, A.; Artigues, Enrique; Peiró, F.; Hostalet, Fernando Oltra; Martín, E.; Cantó, A.

doi:10.1016/s0300-2896(15)30484-1

Cited by 8 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yet in the WHO classification of lung tumours of 1999, bronchial carcinoid tumours are still mentioned as a subgroup of epithelial lung tumours [5]. Carcinoid tumours account for at least 0.4% of lung tumours in epidemiological studies [6] and up to 5% in surgical series [7]. Based on histology, bronchial carcinoids can be classified in two groups: typical (around 85%) and atypical (around 15%) [8].…”

Section: Introductionmentioning

confidence: 99%

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Essen

Krenning

Bakker

et al. 2007

Eur J Nucl Med Mol Imaging

116

View full text Add to dashboard Cite

Purpose Foregut carcinoid tumours have a different embryological origin than other gastroenteropancreatic neuroendocrine tumours (GEP NETs). In the total group of GEP NETs (n=131), treatment with 177 Lu-octreotate resulted in tumour remission in 47% of patients, with a median time to progression (TTP) of >36 months. As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin. Methods Nine patients with bronchial, five with gastric and two with thymic carcinoids were treated. All patients had metastasised disease. The intended cumulative dose of 177 Lu-octreotate was 22.2-29.6 GBq. Southwest Oncology Group criteria were used for response evaluation.

show abstract

Section: Introductionmentioning

confidence: 99%

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Essen

Krenning

Bakker

et al. 2007

Eur J Nucl Med Mol Imaging

116

View full text Add to dashboard Cite

show abstract

“…Posteriormente Kramer, en 1930, estableció su entidad clínica y patológica 3 . Hampel en 1937 los separó del resto de tumores benignos, denominándolos adenomas bronquiales 3,5,6 . En 1944, Engelbreth reconoció que algunos de ellos podían ser más agresivos 6 .…”

Section: Discussionunclassified

“…Se presentan a cualquier edad, con mayor frecuencia alrededor de los 50 años [1][2][3] , aunque se describen casos en ancianos y excepcionalmente en niños 1,3 . No presentan diferencias en relación al sexo 1,3 .…”

Section: Discussionunclassified

“…Poseen un estroma fibrovascular abundante, lo que favorece el sangrado 2 . Invaden localmente y desarrollan metástasis a distancia 3 , pudiendo presentar recidiva locorregional. Se asocian a otros tumores pulmonares en 11.5% 5 .…”

Section: Discussionunclassified

“…Se clasifican en típicos y atípicos, según los criterios de Paladugu 3,6 . El típico tiene hasta 2 mitosis por campo, ausencia de necrosis, razón núcleo/citoplasma baja, patrón celular organizado, moderada hipercromasia nuclear, bajo porcentaje de metástasis regionales y ausencia de metástasis a distancia.…”

Section: Discussionunclassified

See 2 more Smart Citations

Tumores carcinoides bronquiales

Jiménez

Butte

2001

cuad.cir

View full text Add to dashboard Cite

Los tumores carcinoides son la neoplasia neuroendocrina más frecuente. Son malignos, tienen un origen epitelial y derivan de las células de Kulchitsky. Cuando tienen un origen bronquial generalmente llevan a la muerte, dado su silencioso crecimiento. Su forma de manifestación es variada, siendo el dolor torácico su principal expresión, aunque pueden ser asintomáticos o sólo ser un hallazgo incidental en una radiografía de tórax. El principal tratamiento es la cirugía, no reportándose mejoría con quimioterapia ni radioterapia asociada. El pronóstico está dado por la histología tumoral, el grado de invasión, localización intrapulmonar y presencia de metástasis. En esta comunicación presentamos 3 casos clínicos de tumores carcinoides bronquiales, tratados en el Hospital Clínico Regional de Valdivia, cuya expresión fue variada.

show abstract

Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour

et al. 2005

View full text Add to dashboard Cite

Typical carcinoid bronchial tumour is a well-known disease that, for years, was considered benign. Currently, it is classified within the group of neuro-endocrine lung tumours. It is a low-grade malignancy tumour with a capability of local and distant recurrence. Complete resection with mediastinal lymphadenectomy is the treatment-of-choice. There are, usually, long-term survivors, even in cases of recurrence or mediastinal node invasion. These patients could benefit from removal of recurrent or metastatic disease. We present, here, a case of a 19-years-old female diagnosed as having N1-bronchial typical carcinoid tumour. She underwent radical surgery, but with mediastinal recurrence and hepatic metastases. A new radical lung resection was performed, and a liver transplant was the therapy-of-choice for the metastatic lesion.

show abstract

Tumores carcinoides bronquiales: Un estudio prospectivo

Cited by 8 publications

References 12 publications

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

Tumores carcinoides bronquiales

Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour

Contact Info

Product

Resources

About